Reevaluating the Amyloid-Beta Paradigm in Alzheimer's Disease (arstechnica.com)

• Limits of protein-focused therapeutic interventions
• Shift toward systemic neuroinflammation models
• Strategic focus on metabolic and vascular health

"The scientific community is undergoing a critical reassessment of the 'Amyloid-Beta' hypothesis, which posits that protein plaques are the primary drivers of Alzheimer's dementia. Despite decades of focus, pharmaceutical success remains limited, prompting a shift toward broader systemic factors including neuroinflammation, mitochondrial dysfunction, and blood-brain barrier integrity. As Europe faces an aging demographic, the strategic focus is moving toward multifactorial therapeutic models that treat Alzheimer's as a metabolic and inflammatory disease rather than solely a protein-misfolding issue, aiming for more resilient health outcomes across the continent."